GTx (GTXI), FDA Agree on Two Ostarine Phase III Designs
Down)
GTx, Inc. (Nasdaq: GTXI) has reached an agreement with the U.S. FDA in regard to design of two Ostarine™ registration Phase IIIs in patients with on-small cell lung cancer (NSCLC).
In July, GTx will initiate the Ostarine POWER1 and POWER2 (Prevention And Treatment Of Muscle Wasting in CancER) Phase III clinical trials and, assuming enrollment for both studies is completed within one year, expects completion of the two five month studies (last patient last visit) in Q412.
Are you missing key trading opportunities? Upgrade to StreetInsider Premium and get a step ahead of the market - FREE TRIAL!
You May Also Be Interested In
- Form 8-K GTX INC /DE/ For: Feb 21
- Wedbush Cuts Price Target on GTX Inc. (GTXI), But Still Sees Some Value
- Novavax (NVAX) Commences Enrollment in Quadrivalent Seasonal VLP Phase II
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
